Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Table 3

Univariate and multivariate analysis of OS in the enrolled cohort.

Variable	No. of cases	Univariate analysis		Multivariate analysis
		HR (95% CI)	value	HR (95% CI)	value
Gender (male versus female)	67/15	0.53 (0.29–0.96)	0.036
Age (≤50 versus >50)	25/57	0.89 (0.52–1.53)	0.669
Tumor size (cm) (≤5/>5–≤10/>10)	37/31/14		0.852
≤5 versus >10	37/14	1.00 (0.51–1.96)	0.991
>5–≤10 versus >10	31/14	0.87 (0.43–1.74)	0.688
AJCC TNM stage (III versus IV)	47/35	1.00 (0.62–1.61)	0.986
ECOG (≤1 versus >1)	72/10	1.44 (0.68–3.04)	0.338
Etiology (HBV/HCV/none HBV, none HCV)	66/6/10		0.849
HBV versus none HBV, none HCV	66/10	0.83 (0.41–1.68)	0.597
HCV versus none HBV, none HCV	6/10	0.76 (0.23–2.48)	0.647
Antiviral therapy (yes versus no)	43/39	1.47 (0.89–2.42)	0.131
Child–Pugh classification (A versus B)	79/3	0.14 (0.03–0.67)	0.014	0.12 (0.03–0.60)	0.010
ALT levels, IU/L (≤40/>40–≤100/>100)	69/11/2		0.152
≤40 versus >100	69/2	0.89 (0.12–6.49)	0.909
> 40–≤100 versus >100	11/2	1.75 (0.22–13.82)	0.594
AFP levels (μg/L) (≤20/20–400/≥400)	22/19/41		0.035
≤20 versus ≥400	22/41	1.95 (1.10–3.47)	0.022
20–400 versus ≥400	19/41	0.89 (0.47–1.66)	0.704
PVTT typing (II/III/IV)	22/44/13		0.878
II versus IV	22/13	1.09 (0.53–2.27)	0.811
III versus IV	44/13	1.18 (0.61–2.28)	0.622
Radiation dose (Gy) (≤50 versus >50)	51/31	1.69 (1.02–2.81)	0.042
Overall response (response versus no response)	43/39	0.41 (0.25–0.69)	0.001	0.41 (0.24–0.68)	0.001
AFP response (≥20% versus <20%)	35/47	0.55 (0.33–0.91)	0.019	0.51 (0.30–0.84)	0.009
Sorafenib (yes versus no)	36/46	0.55 (0.33–0.90)	0.018